360Dx

360Dx is a publication from GenomeWeb, an independent news source located in New York. Since its inception in 1997, GenomeWeb has been dedicated to supporting the worldwide community of scientists, tech experts, and leaders involved in creating and utilizing cutting-edge tools for molecular biology research and diagnostics. GenomeWeb operates as a division of Crain Communications.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#1271048

United States

#536299

Health/Biotechnology and Pharmaceuticals

#516

Traffic sources

Monthly visitors

Articles

Quanterix Cuts 2025 Guidance Due to Tariffs, Academic Funding, as Q1 Revenues Fall 5 Percent

3 days ago | 360dx.com | Adam Bonislawski

NEW YORK – Citing tariffs, cuts to academic funding, and lower biopharma spending, Quanterix on Monday lowered its full-year 2025 revenue guidance to between $120.0 million and $130.0 million.
New Grail Publication Explores Optimal Liquid Biopsy MCED Test Interval for Mortality Impact

6 days ago | 360dx.com | Molika Ashford

NEW YORK – Multi-cancer early detection (MCED) firm Grail published a new study on Thursday that expands on earlier modeling work to analyze the impact of different testing intervals on the ability of its Galleri circulating tumor DNA (ctDNA) assay to shift cancer diagnoses across a population to earlier, more treatable stages.
Natera Ramping up R&D, Commercial Spending as Q1 Product Revenues Rise 37 Percent, Beat Estimates

1 week ago | 360dx.com | Forest Ray

NEW YORK – Natera is ramping up its R&D investments and expanding its commercial operations to take advantage of rising sales of its Signatera test for cancer recurrence and to solidify its presence in other fields such as genitourinary cancer.
Accelerate Diagnostics Bankruptcy Comes After Years of Difficulty

1 week ago | 360dx.com | Kelsy Ketchum

NEW YORK – Although it had multiple products with regulatory clearance and technology that had been validated by outside users, Accelerate Diagnostics' inability to attract buyers for its instruments doomed the company. On Thursday the Tucson, Arizona-based developer of antibiotic susceptibility testing platforms and assay filed for Chapter 11 bankruptcy protection in the US Bankruptcy Court for the District of Delaware.
Veracyte Q1 Revenues up 18 Percent, Driven by Core Tests

1 week ago | 360dx.com | Molika Ashford

NEW YORK – Veracyte said Wednesday that its first quarter 2025 revenues were up 18 percent compared to the same quarter of 2024.
Siemens Healthineers Expecting up to €300M Tariff Hit in Near Term

1 week ago | 360dx.com | Greg Cima

Note: This story has been updated with comments from a conference call to discuss the firm's financial results. NEW YORK – Siemens Healthineers said Wednesday that it expects tariffs implemented by the Trump administration will reduce its second half adjusted earnings before interest and taxes by €200 million ($227 million) to €300 million and its fiscal year adjusted earnings per share by €.15, although the firm posted growth in its Q2 diagnostics business and total revenues.
Bio-Techne Prepared to 'Minimize Impact' of Tariffs as Fiscal Q3 Revenues Rise 4 Percent

1 week ago | 360dx.com | Kelsy Ketchum

Note: This story has been updated with comments from the conference call to discuss the firm's financial results. NEW YORK – Despite macroeconomic uncertainty related to tariffs announced by President Donald Trump last month, Bio-Techne executives said the company is well positioned to mitigate the impact of tariffs by the end of fiscal 2025.
UPDATE: Siemens Healthineers Expecting up to €300M Tariff Hit in Near Term

1 week ago | 360dx.com | Greg Cima

Note: This story has been updated with comments from a conference call to discuss the firm's financial results. NEW YORK – Siemens Healthineers said Wednesday that it expects tariffs implemented by the Trump administration will reduce its second half adjusted earnings before interest and taxes by €200 million ($227 million) to €300 million and its fiscal year adjusted earnings per share by €.15, although the firm posted growth in its Q2 diagnostics business and total revenues.
PAMA Reform Again a Top Lab Priority, but CBO Scoring, Congressional Chaos Add Complications

1 week ago | 360dx.com | Adam Bonislawski

NEW YORK – Reform of the Protecting Access to Medicare Act (PAMA) is once again a top priority for the clinical lab industry, but chaos in Washington D.C. could make legislative action a hard lift. And while in each of the last six years, Congress has passed one-year delays to PAMA reporting requirements and reimbursement cuts, such relief could be less likely this year, warned several industry stakeholders last week at the Executive War College (EWC) annual meeting in New Orleans.
UPDATE: Siemens Healthineers Expects up to €300M Tariff Hit in Near Term as Fiscal Q2 Dx Revenues Rise 2 Percent

1 week ago | 360dx.com | Greg Cima

Note: This story has been updated with comments from a conference call to discuss the firm's financial results.